หน้าแรก
ค้นหา
Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma
Website: https://www.onclive.com Twitter: / onclive Facebook: / onclive LinkedIn: / onclive
แสดงข้อมูลเพิ่มเติม 1
Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma
Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma
Dr. Weber on CheckMate-238 Compared to Other Trials in Melanoma
Dr. Weber on CheckMate-238 for Melanoma
4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma
Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma
Impact of CheckMate-238 Results for Patients With Melanoma
Jeffrey S Weber, ASCO 2018 – Resected stage III melanoma and the CheckMate 238 trial
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma
How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care
Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma
Dr. Weber on Research Efforts Examining Neoadjuvant Approaches in Melanoma
Dr. Weber on Nivolumab Versus Chemotherapy in Advanced Melanoma
Checkmate 238 results presented at ESMO 2017
Dr. Weber on Next Steps With Pembrolizumab as Melanoma Treatment
Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS
Copy of Dr. Weber on the FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF-Mutant Melanoma
Adjuvant nivolumab in patents with high-risk resected melanoma